Study to Investigate the Absorption, Metabolism and Excretion of [14C] AC0010 in Patients With Advanced NSCLC

Carcinoma, Non-Small-Cell Lung Clinical Trial

Official title:

An Open-Label, Non-Randomized, Single-Center Study to Determine the Absorption, Metabolism and Excretion of A Single Dose [14C] AC0010 in Patients With Advanced NSCLC

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03001609
• Other study ID #: AC201606AVTN06
• Status: Completed
• Phase: Phase 1
• First received: December 19, 2016
• Last updated: September 29, 2017
• Start date: November 2016
• Est. completion date: September 2017

Study information

• Verified date: September 2017
• Source: Hangzhou ACEA Pharmaceutical Research Co.,Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to investigate Pharmacokinetics parameters of a single dose [14C] AC0010 in male Patients With Advanced NSCLC.

Description:

The purpose of this study is to investigate the Absorption, Metabolism, Excretion and Pharmacokinetics of a single dose [14C] AC0010 in male Patients With Advanced NSCLC.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 7
• Est. completion date: September 2017
• Est. primary completion date: August 2017
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

• signed and dated informed consent

• histologically or cytologically confirmed diagnosis of local advanced or recurrent NSCLC

• failed to the treatment of EGFR-TKI and harbored T790M mutation

• male, Age 18~ 65, have a body mass index (BMI) >19 kg/m2

• ECOG PS:0-1,Life expectancy of more than 3 months

• main organs function is normal, laboratory values as listed below: blood test without blood transfusion within 14 days

1. Haemoglobin >100 g/L

2. Absolute neutrophil count =2.0x10^9/L or WBC =3.5 x10^9/L

3. Platelet count = 80x10^9/L

4. Total bilirubin =1.5xULN

5. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) = 2.5 times upper limit of normal (ULN)

6. BUN=1.5xULN

7. Serum creatinine =1.5xULN or creatinine clearance ratio =60 mL/min

• Any prior treatment (chemotherapy, radiotherapy or surgery) must be completed over 4 weeks(target therapy over 2 weeks) from the screening; Patients must have recovered from all toxicities related to prior anticancer therapies to grade = 1 (CTCAE v 4.03)

• International normalized ratio (INR) = 1.5

• Patients and their partners should be willing to use methods of contraception or total abstinence from start of dosing until 6 months after discontinuing of study treatment

Exclusion Criteria:

• Prior treated with AC0010 or allergic to drug or its formulation ingredients

• Patients receiving other anti-tumor therapy

• Impairment of GI disease, renal disorders or liver disease that may significantly alter the absorption and metabolic of AC0010 (e.g., Unable to swallow, liver, kidney or gastrointestinal partial resection, chronic diarrhea and intestinal obstruction)

• HCVAb positive, active hepatitis B (excluding HBV carriers), Hepatitis virus markers positive and receiving anti-virus drugs

• Meningeal metastasis; brain metastasis with whole brain radiotherapy; prior received hormones or mannitol for the brain metastasis

• Previous EGFR-TKI treatment related Interstitial lung disease history

• Known human immunodeficiency virus infection (HIV), other acquired or congenital immunodeficiency disease, or a history of organ transplantation

• Any severe and / or uncontrolled active infections

• Patients receiving concomitant immunosuppressive agents or high-dose corticosteroids

• Any severe and / or uncontrolled medical conditions

• Patients being treated with drugs recognized as being inhibitors or inducers of the liver isoenzyme in the last 4 weeks prior to registration in the current study

• Within 3 days prior to the treatment intaking of pitaya, pomelo, grapefruit, orange, mango and other fruit may affect drug metabolizing enzymes or juice

• Within 2 days prior to the treatment intaking of coffee, tea, cola, chocolate, or other caffeine containing beverages, alcoholic beverages and / or other alcoholic products

• Major surgery, incisional biopsy or traumatic injuries;

• Within 4 weeks prior to the screening patients with bleeding = grade 3, non-healing wound, sever ulcer or bone fracture

• Patients received high dose irradiation treatment or other 14C-labeled drug within 1 year

• Known a history of alcoholism or drug abuse

• Nicotine or urine drug testing was positive

• Participate in any clinical trial within 4 weeks prior to the screening

• Investigator judgment that patient is unsuitable to participate in study

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung

Intervention

Drug:
• AC0010
Oral dose of 14C-labeled AC0010 suspension including 200 mg/83µCi[14C]

Locations

Country	Name	City	State
China	Jiangsu Province Hospital	Nanjing	Jiangsu

Sponsors (1)

Lead Sponsor	Collaborator
Hangzhou ACEA Pharmaceutical Research Co.,Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Pharmacokinetics, Cumalative excretion and Metabolite of 14C-labeled AC0010	Pharmacokinetics of 14C-labeled AC0010 Radioactivity in whole blood and plasma,Cumulative excretion of 14C-labeled AC0010 radioactivity in feces and urine,Metabolite identification of 14C-labeled AC0010 in plasma, urine and feces	up to 8 Days
Secondary	Quantitative analysis of plasma concentrations of unlabeled AC0010	Quantitative analysis of plasma concentrations of unlabeled AC0010 using a validated LC-MS/MS method	up to 8 Days
Secondary	Number of adverse events (AE) experienced by patients	Number of adverse events (AE) experienced by patients to assess safety and tolerability	up to 8 Days